AptarGroup, Inc. (NYSE:ATR) Q1 2022 Earnings Conference Call April 29, 2022 9:00 AM ET Company Participants Matt DellaMaria - SVP, Investor Relations and Communications Stephan Tanda - President and CEO Bob Kuhn - Executive Vice President and CFO Conference Call Participants George Staphos - Bank of America Merrill Lynch Mark Wilde - BMO Capital Markets Kyle White - Deutsche Bank Adam Josephson - KeyBanc Capital Markets John Gillen - William Blair & Company Gabe Hajde - Wells Fargo Securities Operator Ladi ...

AptarGroup Inc. (NYSE:ATR) Q4 2021 Earnings Conference Call February 18, 2022 9:00 AM ET Company Participants Matt DellaMaria - SVP, Investor Relations and Communications Stephan Tanda - President and CEO Bob Kuhn - Executive Vice President and CFO Conference Call Participants George Staphos - Bank of America Merrill Lynch Ghansham Panjabi - Robert W. Baird Mark Wilde - BMO Capital Markets Kyle White - Deutsche Bank John Kreger - William Blair & Company Adam Josephson - KeyBanc Capital Markets Gabe Hajde - ...

Financial Performance - Q4 2021 - Reported sales growth was +9%[10], with core sales growth of +10%[10] - The Food + Beverage segment experienced double-digit core sales growth, with approximately 60% of the growth attributed to price adjustments[25] - Adjusted EPS and EBITDA were impacted by restructuring initiatives, net unrealized investment loss, and transaction costs related to acquisitions[31] Financial Performance - Full Year 2021 - The company achieved record annual sales, driven by top-line growth across each segment[38] - Core sales growth was 7%, supported by broad-based demand and price adjustments[38] - Reported EPS increased by 12% from FY 2020 to FY 2021[37] Segment Performance - The Pharma segment experienced solid growth in Q4, driven by demand for solutions for vaccines, injected medications, and Active Materials, with a ~50% increase in Active Materials sales due to Activ-Film™ technology[12] - The Beauty + Home segment's growth was primarily driven by price initiatives and increased demand for dispensing systems for fragrance, skincare, and hair care products[25] Strategic Initiatives and Investments - The company is expanding capacity for elastomeric components in France and the U S, with a $55 million investment (net of government grants)[54] - A new facility in Suzhou, China is being built with a $31 million investment to optimize the company's footprint[54]

AptarGroup Inc. (NYSE:ATR) Q3 2021 Earnings Conference Call October 29, 2021 9:00 AM ET Company Participants Matt DellaMaria - SVP, Investor Relations and Communications Stephan Tanda - President and CEO Bob Kuhn - Executive Vice President and CFO Conference Call Participants George Staphos - Bank of America Securities Ghansham Panjabi - Baird Mark Wilde - BMO Capital Markets Kyle White - Deutsche Bank Gabe Hajde - Wells Fargo Adam Josephson - KeyBanc Angel Castillo - Morgan Stanley Daniel Rizzo - Jeffries ...

Financial Data and Key Metrics Changes - Reported sales increased by 16% and core sales grew by 10% compared to the previous year, with EBITDA improvement noted [6][19] - Adjusted earnings per share rose by 7% to $0.91, while adjusted EBITDA increased by 8% to $148 million [19][20] - The overall adjusted EBITDA margin would have been approximately 180 basis points higher without the negative inflation impact [19] Business Line Data and Key Metrics Changes - Pharma segment saw a core sales growth of 2%, with a 14% increase in sales to the injectables market, primarily driven by vaccine administration [20][21] - Beauty + Home segment reported a 13% increase in core sales, with 75% of the growth attributed to increased volumes [22][23] - Food + Beverage segment experienced a 23% increase in core sales, with 60% of this growth coming from price adjustments due to higher resin costs [24] Market Data and Key Metrics Changes - Core sales to the prescription market decreased by 7%, while consumer healthcare sales fell by 1% due to inventory destocking [21] - Core sales to the beauty market increased by 28%, while personal care sales decreased by 1% as hand sanitizer demand normalized [23] - Core sales to the food market increased by 21%, and beverage market sales rose by 26% as demand for home cooking continued [24] Company Strategy and Development Direction - The company is actively pursuing M&A opportunities, including the acquisition of Voluntis and Weihai Hengyu Medical Products to strengthen its position in digital health and injectable markets [10][11] - Focus on sustainability initiatives and partnerships to promote a circular economy, including a collaboration with REBO for reusable products [11][12] - The company aims to expand capacity in high-growth regions and markets while maintaining a strong balance sheet with a leverage ratio of approximately 1.5 [26][29] Management's Comments on Operating Environment and Future Outlook - Management anticipates a gradual recovery in the beauty, beverage, and prescription pharma businesses, with a stronger performance expected towards the end of the year [28][29] - The ongoing uncertainty regarding economic recovery and customer caution may impact short-term performance, particularly in the prescription drug market [25][28] - Management remains optimistic about the long-term outlook, emphasizing the importance of strategic investments for future growth [29] Other Important Information - The company was recognized among the top 50 companies for ESG performance, highlighting its commitment to sustainability [12] - The board welcomed a new member, Candace Matthews, who brings extensive experience in various industries [13] Q&A Session Summary Question: Corporate expense increase - The increase was driven by strategic activities and variable costs, with expectations to stabilize between $14 million and $15 million going forward [33] Question: Pharma segment performance - The prescription market's decline is attributed to inventory destocking, with expectations for recovery in Q4 based on customer conversations [34][36] Question: Impact of acquisitions - The Weihai Hengyu acquisition enhances local supply capabilities in China, while Voluntis strengthens digital therapy capabilities [38][39] Question: Visibility on elastomer business - The company has a broad order portfolio for both COVID and traditional vaccines, indicating confidence in continued growth [46] Question: Inflationary pressures - Inflation negatively impacted margins, with expectations for a net negative impact in Q3, though improvements are anticipated [49][86] Question: Recovery in Beauty and Home segment - The segment is approaching pre-COVID levels, with Q2 volumes at about 95% of 2019 levels [61] Question: Overall impact of the pandemic on Pharma - The pandemic has had a net positive impact on the Pharma business, increasing exposure to new customers and driving innovation [82]